HomeAI · summaries
Storia in 3 fonti
Emcure's Poviztra gets CDSCO approval for fatty liver treatment
Emcure's semaglutide brand Poviztra has received CDSCO approval for treating MASH, expanding access to fatty liver treatment in India.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindu.com
India approves Novo Nordisk’s weight loss drug Wegovy for fatty liver disease
The Central Drugs Standard Control Organization (CDSCO) has approved Danish major Novo Nordisk’s weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication —…
- ·
thehindubusinessline.com
Emcure's Poviztra gets CDSCO approval for fatty liver treatment
Emcure's semaglutide brand Poviztra has received CDSCO approval for treating MASH, expanding access to fatty liver treatment in India.
- ·
economictimes.indiatimes.com
Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment
Emcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treating metabolic dysfunction-associated…
- ·
Now Emcure’s injectable semaglutide brand Poviztra can be used to treat liver condition
Emcure’s Poviztra, an injectable semaglutide, is now approved to treat liver condition MASH in India.